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15 different GP practices across Ireland who were deemed suit-
able by their physician to start treatment with SFC (any dose).
HRQOL was assessed using the SF-36 before treatment and 12
weeks later following treatment. RESULTS: Data was evaluable
for 90 patients (71%; asthma, 21%; COPD, 8%; bronchitis or
cough). Fifty-four percent of patients were female and 33% were
over 60 years of age. At baseline, HRQOL scores for all health
attributes for all patients was less than that of the general popu-
lation. The biggest difference was in the role physical and general
health attributes (37 and 24 points respectively). After 12 weeks,
SFC had a signiﬁcant positive impact on most health attributes.
The biggest improvements were observed in the role physical,
vitality, social functioning and role emotional attributes with an
average difference of 15.5, 11.5, 11.1 and 10.9 points respec-
tively (all p < 0.004). CONCLUSION: This study showed that
respiratory diseases have a negative impact on patient’s quality of
life. However, treatment with SFC resulted in positive improve-
ments in the quality of life of patients with respiratory diseases
like asthma and COPD.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD)
imposes a tremendous economic and humanistic burden on
health care systems worldwide. The EQ-5D is a generic measure
of health-related quality of life (HRQL) that can help to better
understand the impact of COPD. The aim of this study was to
estimate EQ-5D index-based utility scores associated with differ-
ent levels of severity of COPD according to Global initiative of
Chronic Obstructive Lung Disease (GOLD) stage. METHODS:
A structured literature search was conducted in EMBASE and
MEDLINE (Jan 1988 to Jan 2007) using keywords relevant to
respiratory disease and EQ-5D. Original research studies in
COPD that reported EQ-5D summary scores were selected for
inclusion. Pooled summary scores for UK-based index were esti-
mated using a ﬁxed-effects estimate for COPD overall and by
GOLD stage (Stage I [least severe] to Stage IV [most severe]).
RESULTS: Of 15 original research studies identiﬁed prior to
screening, 8 reported EQ-5D index-based summary scores by
severity. Utility scores which ranged from 0.52 (SD 0.16) to 0.84
(SD 0.15). Pooled average utility scores (95% CI) by GOLD
stage were as follows: stage I = 0.74 (0.62–0.87); stage II = 0.74
(0.66–0.83); stage III = 0.69 (0.60–0.78); and stage IV = 0.61
(0.44–0.77). CONCLUSION: Synthesis of the current literature
provided evidence that HRQL decreases with severity of COPD.
Utilities associated with stage of severity may be useful for
modeling outcomes and facilitating quality-adjusted life-year
calculations in economic evaluations of COPD.
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OBJECTIVES: To model the relationship between St George’s
Respiratory Questionnaire for Chronic Obstructive Pulmonary
Disease (SGRQ-COPD) and utilities based on EQ-5D so as
to estimate preference-based utilities for COPD patients.
METHODS: Dataset comprised of a one-year clinical study of
845 patients. 559 patients completed all items of the SGRQ-
COPD and EQ-5D at baseline. Ordinary least squares regression
was used to predict EQ-5D utilities based on responses to SGRQ-
COPD. Following identiﬁcation of signiﬁcant patient character-
istics, signiﬁcant components and individual items measured in
SGRQ-COPD were included using stepwise selection regression
with an additive speciﬁcation to obtain the preferred algorithm
to explain EQ-5D utilities. Adjusted R-squared and error of
prediction (root mean-squared error: RMSE), were used to judge
goodness of ﬁt. The preferred algorithm was validated for pre-
dictive ability using end of trial data. RESULTS: The preferred
algorithm included the following terms (coefﬁcient): constant
(+1.0050), symptoms (-0.0006), activity (-0.0019) and impacts
(+0.0019) component scores, one activity item—Item 27 ‘I take a
long time to get washed or dressed’ (-0.0780), one symptom
item—Item 5—‘I have had 3 or more attacks of chest trouble in
the last year’ (-0.0480), and two patient characteristics, smoking
history (-0.0160) and gender (+0.0304). Adjusted R-squared
was 43.45% and RMSE was 0.1452. In the validation analysis,
this algorithm explained 39% of the variation in utilities derived
from EQ-5D. The algorithm that excluded items 27 and 5, but
included all three components and two patient characteristics,
had adjusted R-squared of 41.11% and RMSE of 0.1482. Alter-
native speciﬁcations applying a logistic transformation and Tobit
regression did not improve on this model. CONCLUSION: The
regression model enables utilities to be estimated for study
patients with SGRQ-COPD measurements but for whom
no preference-based instrument has been administered. The
approach appears fairly robust based on the explanatory power
of the algorithm and validation results.
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OBJECTIVES: Agencies such as NICE in the UK have speciﬁc
requirements for economic evaluations. NICE specify how utility
data should be collected and used in such analyses. The present
review aimed to: 1) identify which utility measures have been
used in asthma and COPD; 2) compare their measurement
properties; and 3) determine if they meet NICE requirements.
METHODS: A literature (Embase, PubMed) and internet
(Google, PROQOLID) search for studies including utility mea-
sures in asthma and COPD was completed for the last 10 years.
It identiﬁed 41 and 24 studies respectively. The evidence regard-
ing each measure was critically appraised and summarised in
terms of our three criteria. RESULTS: Asthma and COPD search
generated 41 and 24 hits respectively. The following generic
instruments had been used in asthma or COPD studies: EQ-5D,
15D, HUI-2, SF-6D [1]. Disease speciﬁc utility measures were
also identiﬁed: ALQ-5D, Asthma Symptoms Utility Index (ASUI)
and the SGRQ-U. The ALQ-5D and the SGRQ-U are derived
from the Asthma Quality of life Questionnaire and St Georges
Respiratory Questionnaire respectively. The EQ-5D has been
most commonly used and one comparison study found it to be
more sensitive than the SF-6D. Measurement properties and
appropriateness for all measures will be summarised. CONCLU-
SION: Utility measures have been quite widely used in asthma
and COPD. EQ-5D, SF-6D, ALQ-5D and HUI-2 would all in
principle be suitable for NICE, but EQ-5D is probably the safest
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